Biocept has announced the commercial availability of its liquid biopsy test for progesterone receptor (PR), which can be used for the detection and monitoring of a key biomarker in the blood of patients with breast cancer. The company noted that the ability to detect PR expression in circulating tumor cells complements its existing ER and HER2 assays for biomarker analysis in breast cancer. Biocept's Target Selector PR expression test is performed on circulating tumor cells using fluorescently labeled antibodies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.